Urofollitropin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Urofollitropin: From Ovulation Induction to Migraine Disorder
One-Sentence Summary
Urofollitropin is a urinary-derived, highly purified preparation of follicle-stimulating hormone (FSH), originally used for ovulation induction and the treatment of female infertility. The TxGNN model predicts it may be effective for Migraine Disorder, but this prediction is currently supported by 0 clinical trials and 0 publications, meaning it rests on model output alone with no corroborating mechanistic or clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ovulation induction / treatment of female infertility (inferred from drug class; no formal UK licence text available) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Urofollitropin is not currently available in this Evidence Pack. Based on known pharmacology, Urofollitropin is a urinary-purified FSH preparation used to stimulate follicular development for ovulation induction and infertility treatment. There is no established biological pathway linking exogenous FSH administration to migraine pathophysiology, which is primarily driven by trigeminovascular system activation and the CGRP (calcitonin gene-related peptide) pathway.
The repurposing rationale accompanying this prediction explicitly notes that the high TxGNN score likely reflects an indirect connection between hormonal and neuroendocrine nodes within the knowledge graph, rather than any specific, validated pharmacological mechanism. No shared pathway, receptor target, or clinical rationale connects the treatment of infertility with migraine management.
Given the absence of a plausible mechanistic link and the complete lack of supporting clinical or literature evidence, this prediction should be interpreted as a graph-topology artefact rather than a genuine repurposing signal at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are currently held for Urofollitropin (total licences: 0). The product’s UK market status is recorded as Not marketed.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications, and drug-drug interaction (DDI) data for Urofollitropin are currently unavailable in this Evidence Pack (flagged as a Blocking data gap — DG001). This absence prevents any preliminary safety assessment (S1 stage) and must be resolved before further evaluation proceeds.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no mechanistic plausibility linking FSH to migraine pathophysiology, and the prediction is unsupported by any clinical trials or published literature (Evidence Level L5 — model prediction only). Combined with a blocking data gap on safety warnings/contraindications, this candidate does not meet the threshold to advance beyond the model-screening stage.
To proceed, the following is needed:
- Resolution of the blocking data gap (DG001): TFDA/MHRA-equivalent SmPC warnings and contraindications
- Confirmed mechanism of action data (DG002), including any neuroendocrine or hormonal pathways plausibly relevant to migraine
- At least preclinical or observational evidence directly linking FSH (or gonadotropin) exposure to migraine frequency/severity
- Independent confirmation that the TxGNN signal is not driven by graph artefacts (e.g., shared node connections unrelated to therapeutic mechanism)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.